Stockscreener 앱 받기
23.61
4.95%
-1.23
전일 마감가:
$24.84
열려 있는:
$24.79
하루 거래량:
2.10M
Relative Volume:
1.12
시가총액:
$2.09B
수익:
$217.42M
순이익/손실:
$-243.25M
주가수익비율:
-8.4466
EPS:
-2.7952
순현금흐름:
$-278.35M
1주 성능:
+8.20%
1개월 성능:
+34.30%
6개월 성능:
+12.43%
1년 성능:
+140.43%
1일 변동 폭
$23.01
$24.79
1주일 범위
$21.24
$25.24
52주 변동 폭
$9.03
$25.59
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
명칭
Syndax Pharmaceuticals Inc
전화
781-419-1400
주소
730 THIRD AVENUE, NEW YORK, MA
Compare SNDX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
23.61 | 2.09B | 217.42M | -243.25M | -278.35M | -2.7952 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-16 | 재개 | H.C. Wainwright | Buy |
| 2025-09-10 | 재개 | Stifel | Buy |
| 2025-09-04 | 재개 | Guggenheim | Buy |
| 2025-08-05 | 재확인 | BTIG Research | Buy |
| 2025-07-10 | 개시 | Goldman | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-06-28 | 개시 | Jefferies | Buy |
| 2024-01-31 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 개시 | Mizuho | Buy |
| 2023-10-25 | 개시 | BofA Securities | Buy |
| 2023-10-11 | 개시 | Goldman | Buy |
| 2023-07-27 | 개시 | Scotiabank | Sector Outperform |
| 2023-07-11 | 개시 | Guggenheim | Buy |
| 2023-04-17 | 재개 | BTIG Research | Buy |
| 2023-01-31 | 개시 | Stifel | Buy |
| 2023-01-03 | 개시 | JP Morgan | Overweight |
| 2022-07-28 | 재개 | B. Riley Securities | Buy |
| 2022-04-11 | 개시 | H.C. Wainwright | Buy |
| 2022-02-15 | 개시 | Goldman | Buy |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-05-25 | 개시 | Citigroup | Buy |
| 2021-02-18 | 개시 | B. Riley Securities | Buy |
| 2020-12-03 | 개시 | Stifel | Buy |
| 2020-05-22 | 업그레이드 | Citigroup | Neutral → Buy |
| 2020-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-05-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-01-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-03-08 | 재확인 | H.C. Wainwright | Buy |
| 2019-01-04 | 개시 | Robert W. Baird | Outperform |
| 2018-01-05 | 개시 | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 개시 | FBR & Co. | Outperform |
| 2017-03-02 | 개시 | Instinet | Buy |
| 2016-10-07 | 개시 | Guggenheim | Buy |
| 2016-03-28 | 개시 | Citigroup | Buy |
| 2016-03-28 | 개시 | JMP Securities | Mkt Outperform |
| 2016-03-28 | 개시 | Morgan Stanley | Overweight |
모두보기
Syndax Pharmaceuticals Inc 주식(SNDX)의 최신 뉴스
Technical Reactions to SNDX Trends in Macro Strategies - Stock Traders Daily
Form 4 Syndax Pharmaceuticals For: 9 July By Investing.com - Investing.com Nigeria
Syndax CEO Michael Metzger sells $784,776 in company stock - Investing.com
Syndax (SNDX) CEO Metzger exercises options and sells 32,375 shares under 10b5-1 plan - Stock Titan
Syndax Pharmaceuticals Insider Sold Shares Worth $784,776, According to a Recent SEC Filing - Moomoo
Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells 32,375 Shares - MarketBeat
Syndax CEO Michael Metzger sells $784,776 in company stock By Investing.com - Investing.com Canada
Form 144 Syndax Pharmaceuticals For: 8 July By Investing.com - Investing.com Nigeria
SNDX insider files to sell 32,375 shares (NASDAQ: SNDX) - Stock Titan
Why Syndax Pharmaceuticals (SNDX) Is Up 6.3% After Broad Russell Value Index Removal And What's Next - simplywall.st
Syndax Pharmaceuticals holds steady as investors await a fresh catalyst - AD HOC NEWS
SG Americas Securities LLC Has $900,000 Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (SNDX) Reports Strong Revuforj Data, Is The Upside Already Priced In? - Sahm
Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals (NASDAQ:SNDX) Draws Fresh Market Attention - Kalkine Media
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Is Syndax Pharmaceuticals, Inc. (SNDX) Stock Still a Biotech Opportunity After Revised AML Market Estimates? - Insider Monkey
Purchase/sale of business (net) of Syndax Pharmaceuticals Inc – SWB:1T3 - TradingView
Price to sales forward of Syndax Pharmaceuticals Inc – MUN:1T3 - TradingView
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Does Syndax Pharmaceuticals’ (SNDX) Russell Value Index Exit Quietly Recast Its Liquidity And Risk Narrative? - simplywall.st
Enterprise value to revenue forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 3000 Value Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView
Trading the Move, Not the Narrative: (SNDX) Edition - Stock Traders Daily
Syndax Pharmaceuticals, Inc.(NasdaqGS:SNDX) dropped from Russell 2000 Value Benchmark - marketscreener.com
Price to earnings forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView
Price to earnings forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Syndax Pharmaceuticals (SNDX) Surges 7.6% as Momentum Builds Past Key SupportButterfly Setup - dars.gov.et
Enterprise value to revenue forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Price to book forward of Syndax Pharmaceuticals, Inc. – NASDAQ:SNDX - TradingView
Price to sales forward of Syndax Pharmaceuticals Inc – DUS:1T3 - TradingView
Price to book forward of Syndax Pharmaceuticals Inc – MUN:1T3 - TradingView
Syndax Pharmaceuticals stock jumps 7.57% as Syndax applauds Dana-Farber's Dr. Armstrong award - Traders Union
Syndax Pharmaceuticals Inc Actuals & Estimates (DUS:1T3) - TradingView
SNDX Forecast — Price Target — Prediction for 2027 - TradingView
H.C. Wainwright Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $40 - Moomoo
1T3 Forecast — Price Target — Prediction for 2027 - TradingView
3 Biotech Takeover Targets Wall Street Is Watching After the Apogee Deal - AOL.com
Syndax Pharmaceuticals (SNDX) Stock Could Be 51.9% Undervalued After SAVE Trial Data - Sahm
Syndax Pharmaceuticals Inc (SNDX) Institutional Confidence - TradingKey
Syndax Pharmaceuticals (SNDX) TD Cowen 46th Annual Health Care Conference Summary - Quartr
Syndax Pharmaceuticals StockLong-term cancer strategy under investor scrutiny - AD HOC NEWS
Is Strong SAVE Trial Data Altering The Investment Case For Syndax Pharmaceuticals (SNDX)? - Sahm
Elmind Capital LP Purchases New Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Catalio Capital Management LP - MarketBeat
Eversept Partners LP Decreases Stock Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Syndax Pharmaceuticals Inc - TradingKey
Apis Capital Advisors LLC Acquires 86,000 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals Inc (SNDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):